CK Life Sciences International (Holdings), Inc. stock analysis
Want to see HK:0775 full AI Analyst Report?
CK Life Sciences International (Holdings), Inc. (0775) Stock Price & Analysis
0775 Stock Chart & Stats
- Day’s Range
- HKD 0.52 - HKD 0.54
- 52-Week Range
- HKD 0.49 - HKD 0.90
- Previous Close
- HKD 0.54
- Volume
- N/A
- Average Volume (3M)
- 1.57M
- Market Cap
- HKD 5.14B
- Enterprise Value
- HKD 11.92B
- Total Cash (Recent Filing)
- HKD 535.65M
- Total Debt (Recent Filing)
- HKD 6.83B
- Price to Earnings (P/E)
- ―
- Beta
- 0.70
- Next Earnings
- Mar 16, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- May 23, 2023
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Diversified Life-Science Activities
Operating across environmental solutions and health-related products gives CK Life Sciences more than one avenue for revenue generation. This breadth can help the company serve different customer needs and reduce reliance on a single product category over the next several quarters.
In-House R&D And Commercialization
In-house research and commercialization capabilities provide a foundation for developing, improving, and scaling life-science products. If execution remains effective, these capabilities can support product renewal and market expansion without relying solely on external innovation.
Meaningful Equity Base
A meaningful equity base and stable asset foundation provide some balance-sheet support despite recent losses and elevated leverage. This capital cushion may help the company continue operating and fund selected priorities while management works to restore profitability and cash generation.
Bears Say
Sharp Profitability Deterioration
The sharp margin contraction and move into operating losses indicate that the current business mix is generating materially weaker economics. Unless margins recover, reduced profitability will constrain reinvestment, weaken earnings resilience, and make sustained growth harder to achieve.
Negative Cash Generation
The reversal from consistently positive operating cash flow during 2020–2024 to negative operating cash flow and substantial free-cash-flow outflow increases funding pressure. Persistently weak cash conversion would reduce flexibility for investment, debt service, and shareholder returns.
Elevated And Rising Leverage
Leverage at roughly 1.75 times equity leaves the company more exposed while profitability and cash generation are weak. Higher debt relative to equity can increase financing demands and restrict capital allocation, making recovery more dependent on improved operating results.
CK Life Sciences International (Holdings), Inc. News
0775 FAQ
What was CK Life Sciences International (Holdings), Inc.’s price range in the past 12 months?
What is CK Life Sciences International (Holdings), Inc.’s market cap?
When is CK Life Sciences International (Holdings), Inc.’s upcoming earnings report date?
How were CK Life Sciences International (Holdings), Inc.’s earnings last quarter?
Is CK Life Sciences International (Holdings), Inc. overvalued?
Does CK Life Sciences International (Holdings), Inc. pay dividends?
What is CK Life Sciences International (Holdings), Inc.’s EPS estimate?
How many shares outstanding does CK Life Sciences International (Holdings), Inc. have?
What happened to CK Life Sciences International (Holdings), Inc.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of CK Life Sciences International (Holdings), Inc.?
What is the TipRanks Smart Score and how is it calculated?
CK Life Sciences International (Holdings), Inc. Stock Smart Score
Company Description
CK Life Sciences International (Holdings), Inc.
CK Life Sciences International (Holdings), Inc. operates as an investment company, which engages in the business of research and development, manufacturing, commercialization, marketing and selling of products and assets in nutraceuticals, pharmaceuticals and agriculture related business. It operates through the following segments: Agriculture-Related and Health. The company was founded on August 10, 2001 and is headquartered in Hong Kong.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ying Choi Yu
- Employees
- 1,920
- Website
- www.ck-lifesciences.com
- Address
- HK
CK Life Sciences International (Holdings), Inc. (0775) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 11 | 6 | 5 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 8 | 0 | 4 |









